Wolverine Trading
BCTX

Wolverine Trading’s Briacell Therapeutics BCTX Stock Holding History

Wolverine Trading’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-90
Closed -$7.73K – 4755
2024
Q4 		$7.73K Buy
+90
New +$10.8K ﹤0.01% 5165

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Wolverine Trading's BCTX Position: Q1 2025 in Review

Wolverine Trading sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 90 shares — an estimated $7.73K sold.

Wolverine Trading first reported a position in BCTX in Q4 2024 and held it in 1 quarter. The position peaked at $7.73K in Q4 2024. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Wolverine Trading reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wolverine Trading sold 90 Briacell Therapeutics shares in Q1 2025, an estimated $7.73K.
  • Wolverine Trading first reported a position in Briacell Therapeutics in Q4 2024 and held it in 1 quarter.
  • Wolverine Trading's Briacell Therapeutics position peaked at $7.73K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Wolverine Trading's 13F filing for Q1 2025, filed 15 May 2025.